NCE-1 Intelligence & Market Opportunity

Vivjoa

Oteseconazole

Antifungal

Oral Capsule

Approval Date

26-Apr-22

NCE-1 Date

26-Apr-26

NCE Date

26-Apr-27

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Oteseconazole

Innovator

MYCOVIA PHARMACEUTICALS, INC.

Dosage Form

Oral Capsule

Strength

150 mg

Therapeutic Category

Antifungal

Usage

To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.